It has become increasingly popular to carry out cost-effectiveness analyses in economic evaluations of healthcare programmes. Cost-effectiveness analysis is based on the maximisation of the health effects for a given amount of resources. However, many published studies fail to report the results of cost-effectiveness analysis in a way that is consistent with this underlying aim. The aim of this article is to demonstrate the decision rules of cost-effectiveness analysis in an easily accessible way for practitioners in the field. A hypothetical example is used to demonstrate the decision rules of cost-effectiveness analysis, and we also show how to estimate the appropriate incremental cost-effectiveness ratios and how to exclude dominated alternatives. It is then shown how fixed budgets or predetermined prices per effectiveness unit can be used as decision rules to maximise health effects and to determine which programmes to implement on the basis of incremental cost-effectiveness ratios. We hope that the article will contribute towards an increased understanding and application of the appropriate decision rules of cost-effectiveness analysis, so that the results of cost-effectiveness analyses can be interpreted meaningfully by decision makers.
[1]
Richard J. Zeckhauser,et al.
Critical ratios and efficient allocation
,
1973
.
[2]
M C Weinstein,et al.
Principles of Cost-Effective Resource Allocation in Health Care organizations
,
1990,
International Journal of Technology Assessment in Health Care.
[3]
M. Hammerton,et al.
THE VALUE OF SAFETY: RESULTS OF A NATIONAL SAMPLE SURVEY. IN: URBAN TRANSPORT
,
1985
.
[4]
I. Kawachi,et al.
The cost-effectiveness of treating mild-to-moderate hypertension: a reappraisal.
,
1991,
Journal of hypertension.
[5]
Göran Karlsson.
Hälsoekonomisk analys av dentala implantat
,
1991
.
[6]
A Gafni,et al.
Cost effectiveness/utility analyses. Do current decision rules lead us to where we want to be?
,
1992,
Journal of health economics.
[7]
H. Sintonen,et al.
Comparing the cost-effectiveness of drug regimens in the treatment of duodenal ulcers.
,
1990,
Journal of health economics.
[8]
M J Buxton,et al.
Economic evaluation of ondansetron: preliminary analysis using clinical trial data prior to price setting.
,
1992,
The British journal of cancer. Supplement.